Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
Globe Newswire•13/10/2026•07:30 ET
0
Key Highlights
- ➤Caspian launched with $50 million financing to fund KO-7246 proof of concept
- ➤KO-7246 entered IND-enabling development ahead of planned Phase 1 diabetes study
- ➤Kura retains approximately half ownership of Caspian after contributing KO-7246 assets
- ➤KO-7246 improved glucose control and expanded beta cells in Type 2 diabetes mice
- ➤Treatment effects persisted one month after withdrawal in responding insulin-deficient rats
Expert Statements
Troy Wilson, President and Chief Executive Officer of Kura Oncology and Executive Chairman of Caspian Therapeutics
“Menin inhibition offers the potential to rebuild the body’s own insulin-producing capacity by expanding existing beta cells”
Troy Wilson, President and Chief Executive Officer of Kura Oncology and Executive Chairman of Caspian Therapeutics
“Caspian was formed to translate this biology into a new approach to treating diabetes.”
Rob Spencer, President and Chief Operating Officer of Caspian Therapeutics
“Our initial clinical objective is to characterize KO-7246’s safety, tolerability and exposure and look for evidence of improved endogenous insulin production in people with either Type 1 or Type 2 diabetes relevant to the broader development opportunity”
Rob Spencer, President and Chief Operating Officer of Caspian Therapeutics
“Assessing measures such as stimulated C-peptide during treatment and follow-up will help us interpret the biological response and guide subsequent development.”
– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity –
– IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production –
Get started
Create a free account to read the full story.